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Abstract
Background: The objective of this clinical study was to assess the potential benefit of a dietary supplement, NP
06-1, on cardiovascular protective properties in overweight and normal weight adults diagnosed with
osteoarthritis of the knee.
Methods: An 8-week, placebo-controlled, randomized, double-blind study was conducted with four groups,
comparing the effects of NP 06-1 to placebo in overweight and normal weight subjects diagnosed with primary
osteoarthritis of the knee. NP 06-1 (a combination of two botanical extracts; Phellodendron amurense bark and
Citrus sinensis peel) or matching placebo was given in a dose of two capsules (370 mg each) twice daily. The
outcome measures reported are lipid levels, weight, BMI, blood pressure and fasting glucose. Analyses of variance
were used to compare changes of physiological measures over the trial period and between groups.
Results: Eighty (80) subjects were enrolled and 45 subjects completed the study. No serious adverse events were
reported. NP 06-1 administration was associated with a general improvement in lipid levels. Both the overweight
and normal weight treatment groups had significant reductions in triglycerides and LDL-cholesterol, as well as a
significant increase in HDL-cholesterol compared to their respective control groups.
Overall there were decreases in blood pressure in both overweight and normal weight treatment groups
compared to respective placebo groups. There was also a significant decrease in fasting glucose levels in the
overweight treatment group compared to the start of the study and to the overweight placebo group. There was
no change in fasting blood sugar for the normal weight groups.
Both overweight and normal weight treatment groups lost a significant amount of weight compared to their
respective placebo groups. The overweight treatment group lost an average of 5% body weight after 8 weeks,
which was associated with a significant loss in BMI over time.
Conclusion: In this pilot study NP 06-1 had a beneficial effect on cardiovascular risk factors; namely lipid levels,
blood pressure and fasting glucose levels. Administration of NP 06-1 was also associated with weight loss.
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Background
Osteoarthritis, the most common form of arthritis, is
characterized by degradation of articular cartilage which
manifests as joint pain followed by reduced mobility. The
origin of the disease is unknown but obesity, joint injury,
metabolic diseases, bone and joint malfunctions, genetic
factors and age have been implicated. Therapies for oste-
oarthritis include weight control, physiotherapy and
pharmacological agents. Conventional drug treatments
include analgesics, anti-inflammatory agents, disease
modifying therapies, hyaluronic acid, intra-articular glu-
cocorticoids and topical analgesic/anti-inflammatory
agents [1]. More recently there has been a focus on nutri-
tional support. Recent systematic reviews highlight the
scientific evidence for potential nutritional and herbal
preparations for those with osteoarthritis [2,3].
A systematic review of the literature covering obese sub-
jects diagnosed with osteoarthritis of the knee concluded
that osteoarthritis related disability could be significantly
improved with a loss of over 5.1% body weight [4].
Besides osteoarthritis related disability, increased body
weight is associated with higher incidence of diabetes,
hypertension and cardiovascular disease. This array of
potential disease risks associated with excess weight has
been termed metabolic syndrome. Individuals with three
or more of the components of central obesity (excess fat
mainly in the abdominal area), hyperinsulinemia, dyslip-
idemia and hypertension are considered to have meta-
bolic syndrome. Treatment involves lifestyle changes such
as diet and exercise, as well as intervention with prescrip-
tion drugs [5].
The subject of this study, NP06-1 (Flavoxine™/Citrofen™,
Next Pharmaceuticals, Inc., Salinas, CA), is a proprietary
product consisting of a blend of extracts of Phellodendron
amurense tree bark and Citrus sinensis (orange) peel stand-
ardized to berberine and polymethoxylated flavones
(PMFs), respectively. NP06-1 was formulated with the
goal of combining the beneficial effects of both the phel-
lodendron and orange peel extracts. There are indications
in the literature, as well as preliminary unpublished stud-
ies conducted by Next Pharmaceuticals, that this combi-
nation might reduce inflammation as well as have
beneficial effects on lipid levels.
The objective of this clinical study was to study the effects
of NP 06-1 compared to placebo on biomarkers related to
cardiovascular health. Both overweight and normal
weight subjects were studied to determine whether or not
there might be a difference in benefits to these two groups.
The effects of NP06-1 compared to placebo in the man-
agement of joint pain and mobility caused by osteoarthri-
tis of the knee will be the subject of another publication.
Methods
Study Design
The clinical trial was designed as a placebo-controlled,
randomized, double-blind study with four groups. Forty
overweight and forty normal weight subjects were
enrolled into either treatment or placebo groups, with
twenty subjects in each group as shown in Table 1. Sub-
jects were recruited via advertisements at the University of
Yaounde I Teaching Hospital, the Djongolo Baptist Hos-
pital and through the public media. The IRB of the Faculty
of Medicine and Biomedical Sciences of the University of
Yaounde I in Cameroon approved the study and all sub-
jects provided informed consent. Dr. Julius Oben, Associ-
ate Professor of Nutritional Biochemistry at the University
of Yaounde I, Cameroon was the principal investigator.
To be included in the study, participants needed to be
men or women, 25 to 60 years of age, diagnosed with pri-
mary osteoarthritis of the target knee using the American
College of Rheumatology guidelines [6] by the treating
physician and confirmed by the clinical investigator, and
with a BMI between 25 kg/m2 to 40 kg/m2 (Overweight
Groups) or 18.9 kg/m2 to 24.9 kg/m2 (Normal Weight
Groups).
The exclusion criteria were: morbid obesity BMI > 40 kg/
m2, diagnosed with rheumatoid arthritis, joint replace-
ments in any one of the knees, unable to walk without
assistance, enrollment in another clinical study in the past
6 months, pregnancy, active infection, autoimmune dis-
ease, AIDS, HIV, active hepatitis, active malignancy, or
diabetes requiring daily insulin management.
Administration and Dosage
NP 06-1 is a proprietary product of Next Pharmaceuticals,
Salinas, California. It is a blend of Phellodendron amurense
Rupr. [Rutaceae] tree bark extract standardized to a mini-
mum of 50% berberine and Citrus sinensis (L.) Osbeck
[Rutaceae] peel extract standardized to a minimum of
30% polymethoxylated flavones (PMF). Berberine and
PMFs were chosen as representative chemical constituents
because they have demonstrated biological activity. Next
Pharmaceuticals has licensed US Patent Nos. 6,184,246
Table 1: Study Groups. 
Group BMI Category Treatment Subjects
OP Overweight* Placebo 20 (13)
OT Overweight* Active 20 (14)
NP Normal weight† Placebo 20 (7)
NT Normal weight† Active 20 (11)
*BMI 25 kg/m2 – 40 kg/m2
† BMI 18.9 kg/m2 – 24.9 kg/m2
The number of subjects initially enrolled is listed; with the number 
that completed the study in parenthesis.Nutrition Journal 2008, 7:16 http://www.nutritionj.com/content/7/1/16
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and 6,987,125 obtained by the USDA for actions
described by PMFs. NP 06-1 is sold under the trade names
Flavoxine™ and Citrofen™.
Subjects were allocated into groups using a random
number table and instructed to take two NP 06-1 capsules
(370 mg formula per capsule) or matching placebo (iden-
tical red two-piece hard shell capsules) with food in the
morning and at night (4 capsules per day) for a total of 8
weeks.
Subjects were instructed to avoid taking analgesics (a 5
day wash-out period prior to enrollment) or cholesterol
lowering medications (a 30 day wash-out period prior to
enrollment) during the study and to stay with their nor-
mal exercise and diet regimens.
Study Variables
The study variables were biomarkers of cardiovascular
health: weight, BMI, triglycerides, total cholesterol, HDL-
cholesterol, LDL-cholesterol, systolic/diastolic blood
pressure and fasting glucose.
Data Collection
Blood samples (8 ml) were collected by venous puncture
at time 0, 4 and 8 weeks. Subjects were requested to come
to the study center on the mornings of each site visit after
a 12-hour fast. The concentrations of triglycerides, HDL-
cholesterol, LDL-cholesterol and fasting glucose, were
measured using commercial diagnostic kits (triglyceride
Infinity, EZ HDL™ cholesterol, EZ LDL™ cholesterol, Glu-
cose Trinder) from SIGMA Diagnostics. Body weight was
determined in 12-hour fasted subjects using a Tanita™
scale and height was measured using a stadiometer.
Safety Assessment
Subjects were given three emergency telephone numbers
to contact during the conduct of the study, if they had any
adverse events or other concerns related to the study. Each
subject was interviewed during site visits to solicit infor-
mation on possible adverse effects they might have
encountered. Participants were instructed to inform the
investigator, if the reason for dropping out of the study
was due to adverse effects.
Statistical Analysis
An analysis of variance model, using repeated measures,
was used to compare changes of physiological measures
over the trial period and between groups. All statistics
were 2-tailed and significance was set at p < 0.05.
Results
Eighty (80) subjects were enrolled in the study and rand-
omized into four groups designated OP (Overweight Pla-
cebo), OT (Overweight Treatment), NP (Normal weight
Placebo) and NT (Normal weight Treatment) (Table 1).
Forty five (45) subjects completed the study and the rea-
sons given by the dropouts are given in Table 2. The drop-
outs were fairly evenly distributed among the groups, with
the exception of Group NP which lost nearly twice as
many participants as the other groups. The majority of
Group NP dropouts cited no improvement in their condi-
tion as their reason for dropping out. There is no indica-
tion that their demographics were different from those
Table 2: Reasons given by subjects for dropping out of the study
Group No. Subjects Reason for drop out
OP 2 Reported no improvement in their condition
1 Nausea and vomiting; Malaria attack
1 Moved out of town
3 No reason given
OT 1 Reported improvement as too slow
1 Tested positive for hepatitis
1 Moved out of town
3 No reason given
NP 7 Reported no improvement in their condition
1N a u s e a
1 Started weight management program
1 Started fasting and stopped treatment
3 No reason given
NT 1 Malaria attack
1N a u s e a
1 Started fasting and stopped treatment
6 No reason givenNutrition Journal 2008, 7:16 http://www.nutritionj.com/content/7/1/16
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who stayed in the study. No serious adverse events were
reported by any of the dropouts or by those who com-
pleted the study.
Baseline lipid levels for the overweight and normal weight
groups were in the normal range. The average levels for
total cholesterol were 194.5 to 197.3 mg/dl, HDL-choles-
terol 63.6 to 69.8 mg/dl, LDL-cholesterol 89.3 to 123.6
mg/dl and triglycerides 86.0 to 124.8 mg/dl. Baseline
blood pressure levels for the overweight and normal
weight groups were in the upper limits of the normal
range, with average levels for systolic blood pressure from
126.6 to 135.8 mmHg and those for diastolic blood pres-
sure from 81.2 to 84.7 mmHg. Baseline fasting blood
sugar values for the groups averaged 56.9 to 113.8 mg/dl,
also in the normal range.
Weight/BMI
In Group OT, the subjects lost a significant amount of
weight and their BMI was reduced compared to the start
of the study (p < 0.001 at 4 and 8 weeks) (Table 3). They
lost an average of 2.5 kg (5.5 pounds, 3.1% of body
weight) after 4 weeks and an average of 4.2 kg (9.2
pounds, 5.1% of body weight) after 8 weeks. There were
smaller, but significant, changes in weight and BMI from
baseline for Group OP. Comparisons of weight loss
between overweight groups revealed that the treatment
group lost on average 3.7 times as much weight as the pla-
cebo group at 8 weeks (9.2 pounds versus 2.5 pounds) (p
< 0.001). However, in comparison, the changes in BMI's
between the two overweight groups were not significant
(Table 4).
In Group NT there was a significant decrease in weight
and BMI at 8 weeks (p < 0.05) compared to baseline
(Table 3). At 8 weeks, this group lost an average of 1.18 kg
(2.6 pounds, 1.8% of body weight). Group NP also had a
significant loss of weight and BMI after 8 weeks compared
to the start of the study (p < 0.01). Comparisons of weight
loss between normal weight groups revealed that the treat-
ment group lost on average 1.5 times as much weight as
the placebo group at 8 weeks (2.6 pounds versus 1.7
pounds) (p < 0.01). There was no significant difference in
change in BMI's between the normal weight treatment
and placebo groups (Table 4).
Total Cholesterol
For Group OT, there were significant decreases in total
serum cholesterol levels at 4 weeks (15.6%) and 8 weeks
(21.6%) compared to baseline (both p < 0.001) (Table 5).
For Group OP, there were smaller, but significant
decreases in total serum cholesterol levels at 4 weeks
(7.2%) and 8 weeks (8.0%) compared to baseline (p <
0.01 and p < 0.05, respectively). Subjects in the treatment
group had a 2.7 times greater average decrease in total
cholesterol in comparison to the placebo group. However
the individual data was highly variable and the change in
Group OT compared to that in Group OP was not signifi-
cant (Table 4).
For Group NT there were significant decreases in total
serum cholesterol at 4 weeks (7.3%) and 8 weeks (9.7%)
compared to baseline (both p < 0.01). For Group NP there
was a significant decrease at 8 weeks (7.3%) but no signif-
icant change after 4 weeks (Table 5). There were no signif-
icant differences between the normal weight groups.
LDL-Cholesterol
For Group OT, there were significant decreases in LDL-
cholesterol levels at 4 weeks (31.0%) and 8 weeks
Table 3: Body Weight, BMI. 
Group Time 0 4 weeks 8 weeks %∆0–4 wks %∆0–8 wks
OP
Weight (kg) 85.0 -1.14 ± 0.96 -1.15 ± 1.30 -1.3* -1.4*
BMI (kg/m2) 31.1 -0.42 ± 0.59 -0.42 ± 0.32 -1.3* -1.4*
OT
Weight (kg) 81.7 -2.49 ± 1.09 -4.19 ± 1.24 -3.1* -5.1*
BMI (kg/m2) 31.7 -0.94 ± 0.11 -1.59 ± 0.11 -3.0* -5.1*
NP
Weight (kg) 67.1 -0.27 ± 0.60 -0.76 ± 0.34 -0.4 -1.1*
BMI (kg/m2) 24.0 -0.10 ± 0.05 -0.28 ± 0.04 -0.4 -1.2*
NT
Weight (kg) 67.0 -0.51 ± 1.08 -1.18 ± 1.29 -0.8 -1.8*
BMI (kg/m2) 24.8 -0.18 ± 0.05 -0.42 ± 0.08 -0.7 -1.7*
*Significant P values < 0.05.
OP = overweight placebo, OT = overweight treatment, NP = normal weight placebo and NT = normal weight treatment.
Values at the start of the study (Time 0) listed in the first column are means of data from individuals. Mean changes after 4 weeks and 8 weeks are 
listed in the second and third columns as ± Standard Deviation. A negative value indicated a decrease in value and a positive number represents an 
increase in value. %∆ values are percent mean change in value between time 0 and either 4 or 8 weeks. Values* are significant P-value comparisons 
(< 0.05) between initial values at Time 0 and either 4 weeks or 8 weeks.Nutrition Journal 2008, 7:16 http://www.nutritionj.com/content/7/1/16
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(44.6%) compared to baseline (both p < 0.001). For
Group OP, there were smaller, but significant decreases at
4 weeks (13.8%) and 8 weeks (14.2%) compared to base-
line (both p < 0.05) (Table 5). Subjects in the treatment
group had an average of 3.1 times greater decrease in LDL
in comparison to the placebo group at 8 weeks (p < 0.01).
For Group NT there were significant decreases in LDL-cho-
lesterol levels at 4 weeks (11.0%) and 8 weeks (16.8%)
compared to baseline (p < 0.05 and 0.01, respectively).
For subjects in Group NP there was a significant decrease
in LDL at 8 weeks (14.5%; p < 0.05); with no significant
change after 4 weeks (Table 5). Comparison of normal
weight groups showed a significant difference between
treatment and placebo at 8 weeks (p < 0.01).
HDL-Cholesterol
For Group OT, there was a significant increase in HDL-
cholesterol levels at 8 weeks (11.8%) compared to base-
line (p < 0.05). There was no significant change at 4
weeks. For Group OP, there were no significant changes in
HDL (Table 5). Subjects in the treatment group had an
Table 4: Inter-Group Analysis Comparing the Paired Treatment to Placebo Groups. 
Group OP vs. Group 0T Group NT vs. Group NP
T = 4 weeks T = 8 weeks T = 4 weeks T = 8 weeks
Weight p < 0.01 p < 0.001 p < 0.05 p < 0.01
B M I N SN SN SN S
Cholesterol p < 0.001 NS NS NS
HDL NS p < 0.001 p < 0.05 p < 0.05
LDL NS p < 0.01 NS p < 0.01
Triglycerides NS p < 0.001 p < 0.01 p < 0.01
Systolic BP NS p < 0.05 p < 0.05 NS
Diastolic BP p < 0.05 p < 0.001 p < 0.05 p < 0.001
Glucose p < 0.001 p < 0.001 NS NS
P-value comparisons are between overweight placebo (OP) and overweight treatment (OT) groups and between normal-weight placebo groups 
(NP) and normal-weight treatment (NT) groups at 4 and 8 weeks. NS = not significant.
Table 5: Lipid Levels. 
Group Time 0 4 weeks 8 weeks %∆ 0–4 wks %∆ 0–8 wks
OP
Cholesterol 195.7 -13.30 ± 12.20 -14.80 ± 16.83 -7.2* -8.0*
HDL 69.8 0.86 ± 0.95 -0.87 ± 5.72 1.2 -1.3
LDL 89.3 -12.64 ± 16.49 -13.01 ± 16.89 -13.8* -14.2*
Triglycerides 124.8 -7.85 ± 10.5 -4.58 ± 7.82 -6.3* -3.7*
OT
Cholesterol 194.5 -31.6 ± 20.68 -43.45 ± 20.96 -15.8* -21.7*
HDL 69.7 3.37 ± 10.64 8.33 ± 13.25 4.8 11.8*
LDL 105.9 -32.99 ± 23.61 -47.47 ± 22.24 -31.0* -44.6*
Triglycerides 118.4 -16.52 ± 21.78 -21.57 ± 22.97 -13.9* -18.1*
NP
Cholesterol 197.3 -9.83 ± 12.91 14.88 ± 13.37 -4.8 -7.3*
HDL 63.6 -0.36 ± 6.91 4.3 ± 4.88 -0.6 6.8
LDL 123.6 -8.82 ± 17.36 -18.02 ± 14.38 -7.1 -14.5*
Triglycerides 86.0 -3.27 ± 2.38 -5.83 ± 8.30 -3.8* -6.8
NT
Cholesterol 197.0 -14.77 ± 15.51 -19.45 ± 16.26 -7.3* -9.7*
HDL 67.3 0.50 ± 4.58 2.63 ± 2.96 0.74 3.9*
LDL 116.0 -12.80 ± 15.86 -19.51 ± 16.89 -11.0* -16.8*
Triglycerides 88.7 -12.33 ± 6.50 -12.82 ± 6.03 -13.9* -14.5*
*Significant P values < 0.05.
OP = overweight placebo, OT = overweight treatment, NP = normal weight placebo and NT = normal weight treatment.
Values at the start of the study (Time 0) listed in the first column are means of data from individuals. Mean changes after 4 weeks and 8 weeks are 
listed in the second and third columns as ± Standard Deviation. A negative value indicated a decrease in value and a positive number represents an 
increase in value. %∆ values are percent mean change in value between time 0 and either 4 or 8 weeks. Values* are significant P-value comparisons 
(< 0.05) between initial values at Time 0 and either 4 weeks or 8 weeks.Nutrition Journal 2008, 7:16 http://www.nutritionj.com/content/7/1/16
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average of 9 times greater increase in comparison to the
placebo group at 8 weeks (p < 0.001).
For Group NT there was a significant increase in HDL-cho-
lesterol levels at 8 weeks (3.9%) compared to baseline (p
< 0.05). There were no significant changes in HDL levels
compared to the start of the study in Group NP. Compar-
ison of normal weight groups showed a significant differ-
ence between treatment and placebo at 4 and 8 weeks
(both p < 0.05) (Table 4).
Triglycerides
For Group OT, there was a significant decrease in plasma
triglyceride levels at 4 weeks (13.9%) and 8 weeks
(18.1%) compared to baseline (both p < 0.05). Group OP
also had a significant decrease in triglyceride levels at 4
weeks and 8 weeks compared to baseline (both p < 0.05)
(Table 5). However there was a greater decrease in the
treatment group in comparison to the placebo group at 8
weeks (p < 0.001).
For Group NT, there was a significant decrease in triglyc-
eride levels at 4 weeks (13.9%) and 8 weeks (14.5%) com-
pared to baseline (both p < 0.001). For Group NP, there
was a significant decrease in triglycerides at 4 weeks but
not at 8 weeks. Comparison of normal weight groups
showed a significant difference between treatment and
placebo at 4 and 8 weeks (both p < 0.01).
Blood Pressure
For Group OT, there was a significant decrease in systolic
blood pressure at 4 weeks (3.3%) and 8 weeks (6.0%)
compared to baseline (both p < 0.05). There was also a
significant decrease in diastolic blood pressure at 4 weeks
(8.3%) and 8 weeks (13.1%) compared to baseline (p <
0.01 and p < 0.001, respectively). There were no signifi-
cant changes in either systolic or diastolic blood pressure
in Group OP (Table 6). Comparison of overweight groups
showed a significant difference between treatment and
placebo in diastolic blood pressure at both 4 and 8 weeks
(p < 0.05 and p < 0.001, respectively) and in systolic
blood pressure at 8 weeks (p < 0.05) (Table 4).
For Group NT, there were no significant changes in systo-
lic blood pressure compared to the beginning of the study.
However there were significant decreases in diastolic
blood pressure at 4 weeks (9.1%) and 8 weeks (11.6%)
compared to baseline (p < 0.05 and p < 0.01, respec-
tively). For Group NP, there was a significant decrease in
systolic blood pressure at 8 weeks (p < 0.05) but not at 4
weeks. This group had significant decreases in diastolic
blood pressure at both 4 and 8 weeks (p < 0.001 and 0.01,
respectively). Comparison of normal weight groups
showed a significant difference between treatment and
placebo in diastolic blood pressure at both 4 and 8 weeks
(p < 0.05 and p < 0.001, respectively). Comparison of
Groups NT to NP also showed a significant difference in
systolic blood pressure at 4 weeks (p < 0.05), but not at 8
weeks (Table 4).
Table 6: Blood Pressure, Fasting Glucose. 
Group Time 0 4 weeks 8 weeks %∆0–4 wks %∆0–8 wks
OP
Systolic BP 130.8 1.31 ± 12.07 2.15 ± 8.66 1.0 1.6
Diastolic BP 81.8 -3.46 ± 7.47 -2.31 ± 8.62 -4.2 -2.8
Glucose 113.8 0.14 ± 7.77 -9.64 ± 8.99 0.2 -10.7
OT
Systolic BP 135.1 -4.43 ± 8.66 -8.07 ± 11.13 -3.3* -6.0*
Diastolic BP 82.7 -6.86 ± 6.98 -10.85 ± 9.00 -8.3* -13.1*
Glucose 73.4 -8.58 ± 11.28 -17.67 ± 11.69 -9.5* -19.6*
NP
Systolic BP 127.0 -5.66 ± 9.56 -6.66 ± 8.08 -4.5 -5.3*
Diastolic BP 84.7 -7.55 ± 2.07 -10.50 ± 5.40 -8.85* -12.39*
Glucose 57.6 -0.18 ± 5.6 -0.02 ± 3.98 -0.3 -0.0
NT
Systolic BP 126.6 2.90 ± 12.60 -2.30 ± 9.21 2.3 -1.8
Diastolic BP 81.2 -7.36 ± 9.34 -9.45 ± 9.96 -9.1* -11.6*
Glucose 56.9 -0.62 ± 5.83 -3.27 ± 7.59 -0.9 -4.8
*Significant P values < 0.05.
OP = overweight placebo, OT = overweight treatment, NP = normal weight placebo and NT = normal weight treatment.
Values at the start of the study (Time 0) listed in the first column are means of data from individuals. Mean changes after 4 weeks and 8 weeks are 
listed in the second and third columns as ± Standard Deviation. A negative value indicated a decrease in value and a positive number represents an 
increase in value. %∆ values are percent mean change in value between time 0 and either 4 or 8 weeks. Values* are significant P-value comparisons 
(< 0.05) between initial values at Time 0 and either 4 weeks or 8 weeks. The unit of measurement for blood pressure is mmHg and for glucose is 
mg/dl.Nutrition Journal 2008, 7:16 http://www.nutritionj.com/content/7/1/16
Page 7 of 8
(page number not for citation purposes)
Fasting Glucose
In Group OT, fasting glucose levels decreased significantly
at 4 weeks (9.5%) and 8 weeks (19.6%) compared to
baseline (p < 0.05 and p < 0.001, respectively) (Table 6).
There were no significant changes in fasting glucose levels
in Group OP. Comparison of overweight groups showed
a significant difference between treatment and placebo at
both 4 and 8 weeks (both p < 0.001) (Table 4).
In Groups NT and NP, fasting glucose levels did not
change significantly from the beginning of the study and
there were no significant differences between the two nor-
mal weight groups.
Discussion
NP 06-1 was administered to the trial participants with a
dose of 4 capsules (1,480 mg) per day with no significant
adverse events reported; an indication of safety.
NP06-1 contains a Phellodendron amurense tree bark extract
standardized to a consistent amount of berberine. NP06-
1 also contains a Citrus sinensis (orange) peel which con-
tains bioflavonoids, including polymethoxylated flavones
(PMFs). Both berberine and PMFs have demonstrated
beneficial effects on lipid levels as well as glucose toler-
ance.
Berberine has been shown in human clinical studies to
have beneficial effects on lipid levels: reducing triglycer-
ides and LDL-cholesterol and in one study increasing
HDL-cholesterol [6,7]. Berberine may affect lipid levels by
increasing expression of hepatic low density lipoprotein
receptor [8]. In a hamster model, citrus PMFs caused sig-
nificant reductions in total cholesterol ranging from 19 to
27%; and in very low density cholesterol (VLDL-C) and
low density cholesterol (LDL-C), ranging from 32 to 40%
[9].
NP 06-1 generally improved lipid levels in this study,
which is consistent with literature reports for berberine
and PMFs. In this study, the overweight and normal
weight treatment groups had significant reductions in trig-
lycerides and LDL-cholesterol compared to their matched
control groups. For HDL-cholesterol, there was a signifi-
cant increase compared to placebo for both treatment
groups. The greatest change in lipid levels was observed
for LDL in the overweight treatment group, which
decreased by an impressive 44.6%. These results indicate
that NP06-1 may have a beneficial effect on cardiovascu-
lar risk factors. High triglycerides, total cholesterol and
LDL-cholesterol levels, along with low HDL-cholesterol
levels, have been established as indicators of risk for car-
diovascular disease [10].
Another risk factor for cardiovascular disease is high
blood pressure [11]. NP06-1 caused significant decreases
in blood pressure in both overweight and normal weight
treatment groups compared to the start of the study and
compared to their respective placebos. There was also a
significant decrease in fasting glucose levels in the over-
weight treatment group compared to the start of the study
and to the overweight placebo group. There was no
change in fasting blood glucose for either normal weight
group.
Both overweight and normal weight treatment groups lost
a significant amount of weight compared to the start of
the study and to their respective placebo groups. The over-
weight treatment group lost an average of 5.1% body
weight after 8 weeks. Weight loss has previously been
reported to decrease fasting glucose levels [12]. Thus
weight loss may have influenced the decrease in fasting
glucose levels observed in this study. The weight loss
appears to be due to NP06-1 as participants were
instructed not to change their exercise or diet regimens.
Further, berberine has been shown to reduce body weight
and to improve glucose tolerance. A mechanism for this is
suggested to be an increase in AMP-activated protein
kinase activity in adipocytes [13].
PMFs have also been shown to decrease insulin levels and
improve glucose tolerance in hamsters [14]. Research is
ongoing on the potential antiatherogenic effects of citrus
flavonoids [15,16].
Conclusion
In a placebo-controlled pilot clinical study, NP06-1
offered several potential health benefits in normal and
overweight subjects with osteoarthritis of the knee. These
potential benefits include significant improvements in
cardiovascular risk factors; namely lipid levels and blood
pressure. There appears to have been additional benefits
to the overweight group compared to the normal weight
group in decreases in fasting glucose. Treatment-induced
weight loss was also observed.
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